Accuray Announces Milestone for Cancer Patients in Melbourne, Australia with First SBRT Treatments Using the CyberKnife® System
Rhea-AI Summary
Accuray (NASDAQ: ARAY) announced that 5D Clinics and JV partner Icon Group treated the first patients in Melbourne using the CyberKnife S7 System on October 8, 2025.
The JV plans to open and operate CyberKnife centers across Australia, initially focusing on the East Coast; alphaXRT is the exclusive distributor and supported installation through first patient treatment. The CyberKnife S7 enables 1–5 outpatient SBRT/SRS sessions versus traditional 30–40 fractions, and the press release cites projected new cancer cases in Australia rising ~50% from 2022 to 2045.
Expansion is noted as subject to Australian regulatory approvals.
Positive
- First CyberKnife S7 patient treatments completed in Melbourne (Oct 8, 2025)
- JV with Icon Group to open multiple CyberKnife centers across Australia
- CyberKnife S7 enables 1–5 outpatient sessions versus 30–40 conventional fractions
- alphaXRT provided installation, training and ongoing service support
Negative
- Rollout initially limited to Australia East Coast, limiting near-term coverage
- Expansion and center openings are subject to Australian regulatory approvals
- Forward-looking expansion outcomes face stated business and macroeconomic risks
News Market Reaction – ARAY
In the Oct 8 session, ARAY gained 7.01%, reflecting a notable positive market reaction. Argus tracked a peak move of +51.9% during that session. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.1x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
5D Clinics and Joint Venture Partner Icon Group Make Strides in Delivering on Commitment to Increasing Access to World-class Radiation Treatments for More Communities Across Australia.
"We couldn't be prouder to announce the first CyberKnife System patient treatments resulting from our partnership with the 5D Clinics and Icon Group joint venture. We have a shared vision and commitment to advancing cancer care globally and the opening of the center in
The number of new cancer cases diagnosed in
One of the first patients treated was David, a 55-year old diagnosed with prostate cancer.
"Choosing the CyberKnife System gave me such relief knowing I didn't have to face surgery or long hospital stays," David said.
"It's allowed me to keep working and get on with life without the downtime of traditional procedures. The results I've seen, and the information from my specialist, have been really reassuring and given me confidence about the future.
"What's also made a difference is being treated here by Dr. Paul Conway — he's been fantastic. Being able to reach out to Paul directly and get the answers I needed is something you don't often experience, and it's made this journey so much easier.
"To anyone starting their cancer journey, I'd say get as much information as you can and connect with specialists who take the time to guide you — that support has been invaluable for me."
5D Clinics in
General Manager for 5D Clinics Australia, Bruno Bosco said this partnership will help turn the dial on cancer care.
"The introduction of the CyberKnife® System to
The CyberKnife S7™ System combines speed, precision, and artificial intelligence (AI) to track and automatically adapt for movement during treatment, delivering the radiation dose directly to the target anywhere in the body. The precision and accuracy of the system enables medical teams to deliver very high doses of radiation in a few days versus conventional fractionation which often require 30-40 sessions. The entire CyberKnife System procedure is typically completed in just 1 to 5 out-patient sessions, making radiation treatments delivered with sub-millimeter precision and accuracy an option for people unable to travel a month or more for care.
alphaXRT is the exclusive distributor, installer and training partner for the Accuray CyberKnife and TomoTherapy® platform portfolios in
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expectations regarding transforming cancer care in
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contact:
Beth Kaplan
Public Relations Director, Accuray
bkaplan@accuray.com
*Subject to Australian regulatory approvals.
1 World Health Organization, International Agency for Research on Cancer. https://gco.iarc.fr/tomorrow/en/dataviz/bars?types=0&sexes=0&mode=population&group_populations=0&multiple_populations=1&multiple_cancers=1&cancers=39&populations=36&apc=cat_ca20v1.5_ca23v-1.5&group_cancers=1. Accessed July 9, 2025.
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-announces-milestone-for-cancer-patients-in-melbourne-australia-with-first-sbrt-treatments-using-the-cyberknife-system-302578017.html
SOURCE Accuray Incorporated